{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:24:12Z","timestamp":1787333052956,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114933","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:28:41Z","timestamp":1787329721000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia"],"prefix":"10.7759","author":[{"given":"Iv\u00e1n","family":"L\u00f3pez-Ibor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Humphery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Tafet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia and schizophrenia spectrum disorders: a nationwide cohort study","volume":"4","author":"Hjorth\u00f8j C","year":"2017","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia and schizophrenia spectrum disorders: a nationwide cohort study. Lancet Psychiatry. 2017, 4:295-301. 10.1016\/S2215-0366(17)30078-0","journal-title":"Lancet Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020, 7:64-77. 10.1016\/S2215-0366(19)30416-X","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial (SEMA-PSY)","volume":"83","author":"Sass MR","year":"2026","unstructured":"Sass MR, Klausen MK, Schwarz CR, et al.. Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial (SEMA-PSY). JAMA Psychiatry. 2026, 83:128-38. 10.1001\/jamapsychiatry.2025.3639","journal-title":"JAMA Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2026.2621191","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality","volume":"27","author":"McIntyre RS","year":"2026","unstructured":"McIntyre RS. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality. Expert Opin Pharmacother. 2026, 27:1-3. 10.1080\/14656566.2026.2621191","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/527530-beyond-weight-loss-glucagon-like-peptide-1-receptor-agonists-and-antipsychotic-adherence-in-schizophrenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:28:42Z","timestamp":1787329722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/527530-beyond-weight-loss-glucagon-like-peptide-1-receptor-agonists-and-antipsychotic-adherence-in-schizophrenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.114933","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}